



LABORATOIRE
DES SCIENCES
DU NUMÉRIQUE
DE NANTES



From clinical data to the artificial pancreas system


Presented by :
Akshita Jain
Master 2 student

Supervised by :
Claude Moog (LS2N)
Emeric Scharbarg (LS2N – CHU de Nantes)


Master Thesis Presentation
August 21, 2020
ECN, Nantes



Glycemic Regulation



Type-1 Diabetes Physiopathology



**No endogenous
Insulin production
=
Hyperglycaemia**

Insulin Injection




What is Type 1 Diabetes ?



- Auto-immune disease
- Epidemiology
 - 40 millions T1D patients in the world
 - 350000 T1D in France
- Incurable disease
- Treatments :
 - Daily insulin injections
 - Insulin pump
- Treatment management : T1D self-care 78 to 305 minutes/day (Shubrook *et al.* 2018)

The Perfect Solution : Artificial Pancreatic Solution

- Uncontrolled chronic blood glucose level lead to severe problems like kidney failure, blindness etc.
- Automatically adjust pump's insulin delivery to keep glucose in safe range.
- Improve and simplify the treatment.
- Reduce manual intervention to inject insulin boluses.




Continuous Glucose Monitoring



Existing Technologies

- Flexible Insulin Therapy (Daily Insulin Injections)
- openAPS
- Android Loopkit
- Diabeloop (MPC)
- Medtronic (PID+MPC)



© Diabeloop 2019

Objectives :

- Incorporate FIT parameters in the Control Law
- Available solutions are hybrid and we need fully automated solution
- Account all the disturbances
- State feedback control over entire glucose-insulin dynamics
- Control Law which incorporates change in FIT parameters (e.g. CIR differs with day time)
- Reduced frequency of hypoglycaemia episodes almost to zero
- Increased percentage of time in target range (70-180 mg/dl)

Chapter - 2 : Glucose-Insulin Dynamics Model

Step-I

- 5 states model comprises of glucose-insulin and meal dynamics which quantify the following state variables :

x_1 = Glucose concentration in blood plasma

x_2 = Insulin Concentration in blood plasma

x_3 = Insulin Concentration in Subcutaneous compartment

x_4 = CHO content (Duodenum to plasma)

x_5 = CHO content (Stomach to duodenum)

u_i = Injected Insulin Rate

u_m = CHO from the meal

θ_1 = Glucose consumption by brain (const. value in mg/dl)

θ_2 = Insulin sensitivity

θ_3 = Response time for insulin dynamics

θ_4 = constant for glucose release from CHO digestion

θ_5 = Response time for CHO dynamics

$$\dot{x}_1 = \theta_1 - \theta_2 x_2 + \theta_4 x_4$$

$$\dot{x}_2 = \frac{-1}{\theta_3} x_2 + \frac{1}{\theta_3} x_3$$

$$\dot{x}_3 = \frac{-1}{\theta_3} x_3 + u_i$$

$$\dot{x}_4 = \frac{-1}{\theta_5} x_4 + \frac{1}{\theta_5} x_5$$

$$\dot{x}_5 = \frac{-1}{\theta_5} x_5 + u_m$$

Chapter - 3 : Implementation of Control Strategy

Step : II



- State Feedback Control Strategy

- Control Output :

$$k\left[\frac{1}{\theta_2}(x_1 - x_{ref}) - \frac{1}{\theta_3}\tilde{x}_2 - \frac{1}{\theta_3}\tilde{x}_3 + \frac{\theta_4\theta_5}{\theta_4}x_4 + \frac{\theta_4\theta_5}{\theta_5}x_5\right]$$

where k is a safety factor and $\tilde{x}_2 = x_2 - \frac{\theta_1}{\theta_2}$ and $\tilde{x}_3 = x_3 - \frac{\theta_1}{\theta_2}$

State Feedback Control Response for 5 states glucose-insulin model



Meal (3 g/Min carbs) introduced at 110 mins for 10 mins.


Target blood glucose is 110 mg/dl.

Time Scale is in Mins.




Step III : Implementation of the Luenberger Observer for Hybrid Control

$$\begin{bmatrix} \dot{\hat{x}}_1 \\ \dot{\hat{x}}_2 \\ \dot{\hat{x}}_3 \\ \dot{\hat{x}}_4 \\ \dot{\hat{x}}_5 \end{bmatrix} = \begin{bmatrix} 0 & -\theta_2 & 0 & \theta_4 & 0 \\ 0 & \frac{-1}{\theta_3} & \frac{1}{\theta_3} & 0 & 0 \\ 0 & 0 & \frac{-1}{\theta_3} & 0 & 0 \\ 0 & 0 & 0 & \frac{-1}{\theta_5} & \frac{1}{\theta_5} \\ 0 & 0 & 0 & 0 & \frac{-1}{\theta_5} \end{bmatrix} \begin{bmatrix} \hat{x}_1 \\ \hat{x}_2 \\ \hat{x}_3 \\ \hat{x}_4 \\ \hat{x}_5 \end{bmatrix} + \begin{bmatrix} 0 & 0 \\ 0 & 0 \\ \frac{1}{\theta_3} & 0 \\ 0 & 0 \\ 0 & \frac{1}{\theta_5} \end{bmatrix} \begin{bmatrix} u_i \\ u_m \end{bmatrix} + \begin{bmatrix} \theta_1 \\ 0 \\ 0 \\ 0 \\ 0 \end{bmatrix} + \begin{bmatrix} L_1 \\ L_2 \\ L_3 \\ L_4 \\ L_5 \end{bmatrix} (y - \hat{y})$$

MATLAB implementation :



Responses of the Luenberger Observer with State Feedback Control



Meal (3 g/Min carbs) introduced at 110 mins for 10 mins.


Target blood glucose is 110 mg/dl.

Time Scale is in Mins.

Chapter 5 : UVA Padova Simulator


Step-IV

- First software model to be approved by FDA for pre-clinical trials of insulin treatments.
- The first model is introduced in 2008 which included 300 in-silico subjects (100 of each age group -adults, adolescents and children) for emulating model parameter database such as FIT parameters.
- The model is revised in 2013 which not only incorporates the non-linearities of insulin action during hypoglycaemia.
- One can modify the meal parameters, select the subjects and hardware based on the test requirements.





UVA Padova Simulator - Graphics User Interface




State Feedback Control Response on UVA Padova Simulator



Meal (3 g/Min carbs) introduced at 110 mins for 10 mins.


Target blood glucose is subject specific.





UVA Padova Simulator - Adolescent Avg.
 State Feedback Control Response (using 5 states
 glucose-insulin observer)
 24 hours scenario with multiple meals introduced
 at Breakfast(7 am), lunch (noon), snacks (4 pm),
 dinner (6 pm) and snacks (11 pm).

Glucose Trace subj: adolescent#average



UVA Padova Results for 1 Day 5 Meals Scenario

Population Group	ID Mean BG	% Time < TGT-low (70 mg/dl)	% Time in target (70-180 mg/dl)	% Time > TGT-high (180 mg/dl)	BG Risk Index
Adolescent	112.04	0.00	100.00	0.00	0.68
Adult	107.40	0.00	100.00	0.00	0.47
Children	124.87	0.00	97.43	2.57	0.73

Medical Time In Range for Clinical Practice :

- Time in Target (70-180 mg/dl) > 60%
- Time in target low (<70 mg/dl) < 5%

Medical Time In Range for Clinical Trial for Hybrid Artificial Pancreas for Adult :





- Time in Target (70-180 mg/dl) > 82%
- Time in target low (<70 mg/dl) < 3%

Extended Luenberger Observer with Unknown Input Observer (UIO) :

Step-V

- $\dot{\hat{x}} = A\hat{x} + Bu + L(y - \hat{y}) + G\hat{d}$
- $\hat{d} = \rho K(y - \hat{y})$
- Conditions :
 - $\text{rank}(CG) = \text{rank}(G) = r$
 - $\text{rank} \begin{bmatrix} A - LC & G \\ C & 0 \end{bmatrix} = n+r$, n is a rank of A-LC
- Finding Value of K & P:
 - $P(A - LC) + (A - LC)^T P = -Q$ where Q is known and, P & Q are symmetric positive definite matrix
 - $G^T P = KC$
- Reference : Corless, M., & Tu, J. (1998). State and input estimation for a class of uncertain systems. *Automatica*, 34, 757–764.

Responses of the UIO with State Feedback Control




Meal (3 g/Min carbs) introduced at 110 mins
for 10 mins.


Target blood glucose is 110 mg/dl.

Time Scale is in Mins.


Step - V : Prototype Development



Offline monitoring



Online monitoring



OpenAPS

Diagnosis of OpenAPS

- Automated glucose monitoring system along with database management and analysis over web protocol.
- Open software development - <https://github.com/openaps/openaps>
- Toolkit comprises of automation program, pump, glucose monitoring system, database (cloud service) and communication devices (including bluetooth, wifi etc.)

Conclusion and Perspectives

- » An observer & state feedback control strategy is implemented and tested with FIT parameters on UVA Padova Simulator for Hybrid Control
- » Achieved desired results for fully automatic control with unknown estimation on 5 state model as Simulator.
- » Prototype Implementation - functional check of control algorithm is complete, full fledged development of state feedback control with UIO and integration with openAPS is in progress.

Thank you for your attention!